Oryzon Genomics, a clinical-phase biopharmaceutical company focused on epigenetics for the development of therapies in diseases with significant unmet medical needs, today announced that the company will present new clinical data and corporate updates at several prestigious international conferences during the months of November and dicember.
The doctor. Carlos Buesa, CEO of Oryzon, will participate and present a corporate update at the conference Jefferies Virtual Healthcare Conference, which will take place from November 16 to 19. Dr. Buesa will hold 1×1 virtual meetings with international investors and companies in the pharmaceutical sector and will make a corporate presentation on November 16 at 09: 20-09: 50 am GMT.
Dr. Buesa will also participate in the conference Evercore ISI 4th Annual HealthCONx Conference which will take place virtually from November 30 to December 2, where he will hold virtual 1×1 meetings with international investors and companies in the pharmaceutical sector. Additionally, Dr. Buesa will give a corporate presentation on November 30 at 08: 25-08: 45 am ET.
The company will present an update of the ongoing Phase II clinical trial with iadademstat, ALICE, with 36-month data, in the 63rd Congress of the American Society of Hematology, ASH-2021, which will be held from December 11 to 14 in Atlanta (USA). The company will present a communication in poster format entitled “Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)” on December 13. ALICE is an open Phase IIa clinical trial, single-arm, which is evaluating the safety, tolerability, dose finding and efficacy of iadademstat in combination with azacitidine in older patients with Acute Myeloid Leukemia on first-line therapy. In accordance with the terms and conditions of embargo of communications established by the organizers of the Congress, the data will be disclosed the same day of the communication in the congress, on December 13.